RECRUITING

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Talk to us

Conditions

Metastatic Non-small Cell Lung Cancer With MTAP DeletionPRMT5Lung cancerNSCLCMTAPCDKN2AMRTX1719First-line

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Official Title

A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Quick Facts

Study Start:2025-10-06
Study Completion:2031-08-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07063745

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
8559073286
Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site#
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Alaska Oncology and Hematology
Anchorage, Alaska, 99508
United States
Local Institution - 0388
Phoenix, Arizona, 85054
United States
Local Institution - 0120
Tucson, Arizona, 85724
United States
Local Institution - 0135
Springdale, Arkansas, 72762
United States
Local Institution - 0407
Los Angeles, California, 90033
United States
Local Institution - 0152
Fort Lauderdale, Florida, 33316
United States
Local Institution - 0389
Jacksonville, Florida, 32224
United States
Local Institution - 0124
Boise, Idaho, 83712
United States
Local Institution - 0333
Lexington, Kentucky, 40503
United States
Local Institution - 0125
Lexington, Kentucky, 40536
United States
Local Institution - 0127
Scarborough, Maine, 04074
United States
Local Institution - 0158
Boston, Massachusetts, 02215
United States
Local Institution - 0420
Traverse City, Michigan, 49684
United States
Local Institution - 0182
Rochester, Minnesota, 55905
United States
Local Institution - 0160
Omaha, Nebraska, 68130
United States
Local Institution - 0179
Hawthorne, New York, 10532
United States
Local Institution - 0128
Rochester, New York, 14642
United States
Local Institution - 0163
Cleveland, Ohio, 44195
United States
Local Institution - 0129
Columbus, Ohio, 43210
United States
Local Institution - 0164
Portland, Oregon, 97213
United States
Local Institution - 0348
Portland, Oregon, 97227
United States
Local Institution - 0433
Dallas, Texas, 75390
United States
Local Institution - 0374
El Paso, Texas, 79915
United States
Local Institution - 0132
Houston, Texas, 77030
United States
Local Institution - 0377
The Woodlands, Texas, 77380
United States
Local Institution - 0354
Salt Lake City, Utah, 84112-5550
United States
Local Institution - 0131
Fairfax, Virginia, 22031
United States
Local Institution - 0186
Richmond, Virginia, 23298
United States
Local Institution - 0145
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-10-06
Study Completion Date2031-08-12

Study Record Updates

Study Start Date2025-10-06
Study Completion Date2031-08-12

Terms related to this study

Keywords Provided by Researchers

  • PRMT5
  • Lung cancer
  • NSCLC
  • MTAP
  • CDKN2A
  • MRTX1719
  • First-line

Additional Relevant MeSH Terms

  • Metastatic Non-small Cell Lung Cancer With MTAP Deletion